Coenzyme Complex Decreased Cardiotoxicity When Combined with Chemotherapy in Treating Elderly Patients with Gastrointestinal Cancer

  • Zhang, Hai-Yan (Department of Cardiology, the Second Affiliated Hospital of Nanjing Medical University) ;
  • Lu, Xiang (Department of Cardiology, the Second Affiliated Hospital of Nanjing Medical University)
  • Published : 2015.05.18


Objective: To investigate the effect of coenzyme complex on decreasing cardiotoxicity in elderly patients with gastrointestinal cancer who were treated by chemotherapy. Methods: From September 2011 to February 2015, we recruited 54 elderly (with more than 70 years of age) patients with gastrointestinal cancer, with advanced disease. Then treated with chemotherapy combined with or without coenzyme complex. After two cycles of treatment, the effect of coenzyme complex on decreasing cardiotoxicity were evaluated. Results: Chemotherapy was combined with coenzyme complex in 32 patients (22man, 10 woman; median age: 74 years, range: 70-87 years) without coenzyme complex in 22 patients (15man, 7 woman; median age: 73 years, range: 70-80 years) with gastrointestinal cancer. Cardiac event was significantly lower in patients treated with chemotherapy combined with coenzyme complex (p<0.01). Conclusions: Coenzyme Complex decreased cardiotoxicity when combined with chemotherapy in treating elderly patients with gastrointestinal cancer.


  1. Alter P, Herzum M, Soufi M, et al (2006). Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem, 4, 1-5.
  2. Doroshow JH, Locker GY, Myers CE (1980). Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest, 65, 128-35.
  3. Ellis JM, Mentock SM, Depetrillo MA, et al (2011). Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. Mol Cell Biol, 31, 1252-62.
  4. Ewer MS, Ali MK, Mackay B, et al (1984). A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol, 2, 112-7.
  5. Holmes FA, Madden T, Newman RA, et al (1996). Sequence-dependent alteration of doxorubicin pharmacokinetic by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol, 14, 2713-21.
  6. Kaul N, Siveski-Iliskovic N, Thomas TP, et al (1995). Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition, 11, 551-4.
  7. Khimji AK, Rockey DC (2010). Endothelin-biology and disease. Cell Signal, 22, 1615-25.
  8. Kim SM, Kwak CH, Lee B, et al (2012). A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. Korean J Intern Med, 27, 342-5.
  9. Kinlay S, Behrendt D, Wainstein M, et al (2001). Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation, 104, 1114-8.
  10. Kohne CH, Folprecht G, Goldberg RM, et al (2008). Chemotherapy in elderly patients with colorectal cancer. Oncologist, 13, 390-402.
  11. Kosmas C, Kallistratos MS, Kopterides P, et al (2008). Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol, 134, 75-82.
  12. Labianca R, Nordlinger B, Beretta GD, et al (2010). Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol, 21, v70-v7.
  13. Lamberti M, Porto S, Marra M, et al (2012). 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res, 31, 60.
  14. Levin ER. Endothelins et al (1995). N Engl J Med, 333, 356-63.
  15. Lipshultz SE, Rifai N, Sallan SE et al (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation, 96, 2641-8.
  16. Li T, Danelisen I, Bello-Klein A, Singal PK (2000). Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res, 46, 523-30.
  17. Liu J, Huang XE, Tian GY, et al (2013). Phase II study on safety and efficacy of Yadanzi (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12.
  18. Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90.
  19. Luwaert RJ, Descamps O, Majois F, et al (1991). Coronary artery spasm induced by 5-fluorouracil. Eur Heart J, 12, 468-70.
  20. MacCarthy PA, Pegge NC, Prendergast BD, et al (2001). The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol, 37, 137-43.
  21. Meydan N, Kundak I, Yavuzsen T, et al (2005). Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol, 35, 265-70.
  22. Meyer CC, Calis KA, Burke LB, et al (1997). Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy, 17, 729-36.
  23. Molyneux SL, Florkowski CM, George PM, et al (2008). Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol, 52, 1435-41.
  24. Ng M, Cunningham D, Norman AR (2005). The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer, 41, 1542-6.
  25. Ozturk MA, Ozveren O, Cinar V, et al (2013). Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction. Blood Coagul Fibrinolysis, 24, 90-4.
  26. Paul DS, Grevengoed TJ, Pascual F, et al (2014). Deficiency of cardiac acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin. Biochim Biophys Acta, 1841, 880-7.
  27. Polk A, Vaage-Nilsen M, Vistisen K, et al (2013). Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev, 39, 974-84.
  28. Rezkalla S, Kloner RA, Ensley J, et al (1989). Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol, 7, 509-14.
  29. Salepci T, Seker M, Uyarel H, et al (2010). 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels. Med Oncol, 27, 416-20.
  30. Siegel R, Naishadham D, Jemal A et al (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  31. Shekelle P, Morton S, Hardy ML (2003). Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease. Evid Rep Technol Assess (Summ), 83, 1-3.
  32. Shimoyama M, Murata Y, Sumi KI, et al (2001). Docetaxel induced cardiotoxicity. Heart, 86, 219.
  33. Shoemaker LK, Arora U, Rocha Lima CM, et al (2004). 5-fluorouracil-induced coronary vasospasm. Cancer Control, 11, 46-9.
  34. Siveski-Iliskovic N, Hill M, Chow DA, et al (1995). Probucol protects against Adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 91, 10-5.
  35. Speyer JL, Green MD, Kramer E et al (1988). Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med, 319, 745-52.
  36. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al (1992). ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol, 10, 117-27.
  37. Sudhoff T, Enderle MD, Pahlke M, et al (2004). 5-Fluorouracil induces arterial vasocontractions. Ann Oncol, 15, 661-4.
  38. Theou O, Brothers TD, Pena FG, et al (2014). Identifying common characteristics of frailty across seven scales. J Am Geriatr Soc, 62, 901-6.
  39. Thyss A, Gaspard MH, Marsault R, et al (1992). Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol, 3, 88.
  40. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, et al (2006). Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol, 25, 305-9.
  41. Untch M, Rezai M, Loibl S, et al (2010). Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 28, 2024-31.
  42. van der Vusse GJ, Glatz JF, Stam HC, et al (1992). Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev, 72, 881-940.
  43. Ventura-Clapier R, Garnier A, Veksler V (2004). Energy metabolism in heart failure. J Physiol, 555, 1-13.
  44. Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6.
  45. Xu X, Wang L, Xu HQ, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4.
  46. Yancik R (1997). Cancer burden in the aged: an epidemiologic and demographic overview. Cancer, 80, 1273-83.<1273::AID-CNCR13>3.0.CO;2-4

Cited by

  1. Effect of protein adsorption on cell uptake and blood clearance of methoxy poly(ethylene glycol)-poly(caprolactone) nanoparticles vol.133, pp.3, 2015,